<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341520</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002059-89</org_study_id>
    <nct_id>NCT03341520</nct_id>
  </id_info>
  <brief_title>Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma</brief_title>
  <acronym>GAZAI</acronym>
  <official_title>Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined modality approach using Obitunuzumab and involved site low dose irradiation in early
      stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders.

      Primary Objective:

      Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in
      combination with Gazyvaro (Obinutuzumab) in early stage nodal follicular lymphoma in order to
      avoid conventional full dose IF radiotherapy.

      Secondary Objective:

      Efficacy and safety of a response adapted radiation dose treatment schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extended field or total nodal irradiation had been the gold standard for early stage
      follicular lymphoma for a long time in Germany. An involved field (IF) irradiation has been
      favored due to the toxicity of large field irradiation in other countries (e.g. USA).
      However, smaller irradiation fields have been accompanied with an increased risk of
      recurrence. A combination of involved field irradiation with the anti-CD20 antibody Rituximab
      (MIR trial) has led to similar efficacy results compared to the large field irradiation but
      with markedly reduced side effects.

      Haas et al. showed in a prospective trial, that a low dose radiation therapy (LDRT) can lead
      to a complete remission in up to 60% in follicular lymphoma. This is presumed to result from
      immune modulatory effects induced by LDRT. The effectiveness of LDRT could also be
      demonstrated in another prospective, randomized British trial (FORT trial: 2 x2 Gy vs. 12 x 2
      Gy) with a CR rate of 40% after 2 x 2 Gy (60% after 12 x 2 Gy). Currently, it is unknown,
      which patients need a higher radiation dose and which not.

      A metabolic complete remission (CR) is an important prognostic marker for progression-free
      survival. According to the results of the PRIMA trial, CR is a very strong predictive
      parameter if the CR is established using FDG-PET.

      In the present GAZAI trial, patients with early stage nodular follicular lymphoma will be
      treated in a combined approach of immunotherapy with an anti-CD20 antibody and small field
      (involved site) irradiation as in the MIR trial. In GAZAI, the fully humanized anti-CD20
      antibody Obinutuzumab (GAZYVARO) will be used, which showed a high efficacy in combination
      with bendamustin in patients with follicular lymphoma refractory to Rituximab (GADOLIN
      trial). In addition, the radiation dose will be limited to 2 x2 Gy in responding patients. A
      dose build-up to a total of 40 Gy (dose in the MIR trial) will be performed in case of
      failure to achieve a complete CR based on a FDG-PET in week 18.

      Primary endpoint of the trial is the rate of CR (based on FDG-PET/CT) after Obinutuzumab and
      2x2 Gy IS radiotherapy in week 18. Secondary endpoints are the morphological CR rate in week
      7, week 18 and month 6, the PFS, the toxicity, the recurrence rate, the recurrence pattern,
      overall survival and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open, non-controlled, national multi-center phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of metabolic response</measure>
    <time_frame>week 18</time_frame>
    <description>rate of metabolic complete remission (CR) after low-dose involved site radiotherapy in combination with Obinutuzumab in patients with initially remaining PET positive lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of morphologic response</measure>
    <time_frame>week 7, week 18, month 6</time_frame>
    <description>rate of morphologic complete remission (CR) after low-dose involved site radiotherapy in combination with Obinutuzumab in patients with initially remaining lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS of all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Start until month 30</time_frame>
    <description>Common Toxicity Criteria (CTC) Toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS of all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>start until month 30</time_frame>
    <description>Relapse rate of all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) EORTC QLQ-C30</measure>
    <time_frame>Initially, week 18, month 12, month 24</time_frame>
    <description>QoL according EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) response</measure>
    <time_frame>initially, week 18, month 6, month 12, month 18, month 24</time_frame>
    <description>Minimal residual disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse pattern</measure>
    <time_frame>start until month 30</time_frame>
    <description>Relapse pattern (e.g. out-field or in-field) of all relapses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) FACT-Lymph25</measure>
    <time_frame>Initially, week 18, month 12, month 24</time_frame>
    <description>QoL according FACT-Lymph25 questionnaires</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Stage I Follicular Lymphoma Grade 1</condition>
  <condition>Stage II Follicular Lymphoma Grade 2</condition>
  <arm_group>
    <arm_group_label>interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab Injection [Gazyva]</intervention_name>
    <description>7x 1000mg flat dose</description>
    <arm_group_label>interventional arm</arm_group_label>
    <other_name>Gazyvaro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low dose radiation Therapy (LDRT)</intervention_name>
    <description>2 x 2 Gy</description>
    <arm_group_label>interventional arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Centrally reviewed CD20-positive follicular lymphoma grade 1/2 based on WHO
             classification (2016)

          -  Untreated (radiation-, chemo- or immunotherapy) nodal lymphoma (including involvement
             of Waldeyer´s ring)

          -  Age: ≥18 years

          -  ECOG: 0-2

          -  Stage: clinical stage I or II (Ann Arbor classification)

          -  Risk profile: Largest diameter of the lymphoma * 7 cm (sectional images)

          -  Written informed consent and willingness to cooperate during the course of the trial

          -  Adequate hematologic function (unless abnormalities are related to NHL), defined as
             follows: Hemoglobin ≥ 9.0 g/dL; absolute neutrophil count ≥ 1.5 × 109/L, Platelet
             count ≥ 75 × 109/L

          -  Capability to understand the intention and the consequences of the clinical trial

          -  Adequate contraception for men and women of child-bearing age during therapy and 18
             months thereafter

          -  Patients with non-active hepatitis B infection (HBsAg neg/HBcAB pos/HBV DNA neg) under
             1-year require prophylactic anti-viral therapy (e.g. Entecavir®) possible (see also
             5.6. Prior and Concomitant Disease)

        Exclusion Criteria:

          -  Extra nodal manifestation

          -  Secondary cancer in the patient's medical history (exclusion: basalioma, spinalioma,
             melanoma in situ, bladder cancer T1a, non-metastasized solid tumor in constant
             remission, which was diagnosed &gt;3 years ago

          -  Concomitant diseases: congenital or acquired immune-deficiency syndromes, active
             infections including viral hepatitis (serology positive for HBsAg or HBcAb in
             combination positive HBV DNA), uncontrolled concomitant diseases including significant
             cardiovascular or pulmonary disease (see also 5.6. Prior and Concomitant Disease)

          -  Severe psychiatric disease

          -  Pregnancy / lactation

          -  Known hypersensitivity against Gazyvaro (Obinutuzumab) or drugs with similar chemical
             structure or any other additive of the pharmaceutical formula of the study drug

          -  Participation in another interventional trial or follow-up period of a competing trial
             which can influence the results of this current trial

          -  Creatinine &gt; 1.5 times the upper limit of normal (ULN) (unless creatinine clearance
             normal), or calculated creatinine clearance &lt; 40 mL/min

          -  AST or ALT &gt; 2.5 × ULN

          -  Total bilirubin ≥ 1.5 × ULN

          -  INR &gt; 1.5 × ULN

          -  PTT or aPTT &gt; 1.5 × the ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herfarth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiation Therapy, University Hospital of Heidelberg ,Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Herfarth, MD</last_name>
    <phone>+49 6221 568202</phone>
    <email>klaus.herfarth@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Soekler, MD</last_name>
      <email>martin.soekler@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kai Hübel, MD</last_name>
      <email>kai.huebel@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Duerig, MD</last_name>
      <email>jan.duerig@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Herfarth, MD</last_name>
      <email>klaus.herfarth@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Johann Schmier, MD</last_name>
      <email>johann.schmier@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Dreyling, MD</last_name>
      <email>martin.dreyling@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TU</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Keller, MD</last_name>
      <email>ulrich.keller@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Buske, MD</last_name>
      <email>christian.buske@uni-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Viardot, MD</last_name>
      <email>andreas.viardot@medizin.uni-ulm.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996 Apr;14(4):1282-90.</citation>
    <PMID>8648385</PMID>
  </reference>
  <reference>
    <citation>Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, Hart AA, van Oers MH, van der Hulst M, Baars JW, Bartelink H. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003 Jul 1;21(13):2474-80.</citation>
    <PMID>12829665</PMID>
  </reference>
  <reference>
    <citation>Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014 Apr;15(4):457-63. doi: 10.1016/S1470-2045(14)70036-1. Epub 2014 Feb 24.</citation>
    <PMID>24572077</PMID>
  </reference>
  <reference>
    <citation>Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11.</citation>
    <PMID>21747087</PMID>
  </reference>
  <reference>
    <citation>Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.</citation>
    <PMID>27345636</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

